Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant advances in the understanding of its etiology and pathophysiology, and the emergence of new therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets, the PAH therapy market is a billion-dollar market that is expected to increase over the coming decade. Our new Current Treatment content provides deep insights into the current treatment of PH/PAH in the United States, and the factors behind those treatment decisions.

Questions Answered:

  • What impact have the launches of novel therapies such as Uptravi, Orenitram, and Adempas, had on prescribing behavior for PH and PAH?
  • What influence has the positive Phase III AMBITION trial, evaluating the upfront dual combination therapy of Letairis and Adcirca, had on the treatment algorithm for PAH?
  • How are specialists utilizing PAH therapies for the treatment of PHWHO groups 2-5?
  • What factors and drug therapy attributes are driving prescribing behavior for the treatment of PAH/PH?


Markets covered: United States

Methodology: Surveys of 51 cardiologists and 53 pulmonologists in the United States, completed in January 2017.

Indication coverage: Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH).

Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Letairis, Adcirca, Bosentan, Revatio, Tyvaso, Remodulin, Veletri, Flolan.

Key companies mentioned: Actelion, Bayer, Gilead, GlaxoSmithKline, United Therapeutics.

Related Reports

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of dr...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details